This joint interagency program, initiated over 4 years ago by the Center for Biologics Evaluation (CBER), Food and Drug Administration (FDA), and the Center for Cancer Research (CCR), National Cancer Institute (NCI), is dedicated to the invention, development, and employment of proteomic technologies for translational bench-to-bedside applications.

The ability to assess and develop proteomic tools for the study of cancer will enable both the FDA and NCI to better understand the promises and limitations of proteomics. Proteomics will undoubtedly impact both the ability of scientists to detect cancer earlier than ever before and allow clinicians to truly tailor therapy. These tools will also allow for new approaches to more effectively determine product safety, potency and purity. These are the ultimate goals of this joint program. Please click on the links above to learn more about each technology.

Questions related to the FDA/NCI Clinical Proteomics Program should be directed to:

Gordan, Whiteley, PhD (gwhitely@ncifcrf.gov)